作者
Reymundo Lozano, Atoosa Azarang, Tanaporn Wilaisakditipakorn, Randi J Hagerman
发表日期
2016
来源
Intractable & rare diseases research
卷号
5
期号
3
页码范围
145-157
出版商
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
简介
The fragile X mental retardation 1 gene, which codes for the fragile X mental retardation 1 protein, usually has 5 to 40 CGG repeats in the 5'untranslated promoter. The full mutation is the almost always the cause of fragile X syndrome (FXS). The prevalence of FXS is about 1 in 4,000 to 1 in 7,000 in the general population although the prevalence varies in different regions of the world. FXS is the most common inherited cause of intellectual disability and autism. The understanding of the neurobiology of FXS has led to many targeted treatments, but none have cured this disorder. The treatment of the medical problems and associated behaviors remain the most useful intervention for children with FXS. In this review, we focus on the non-pharmacological and pharmacological management of medical and behavioral problems associated with FXS as well as current recommendations for follow-up and surveillance.
引用总数
2016201720182019202020212022202320241111211101119157
学术搜索中的文章
R Lozano, A Azarang, T Wilaisakditipakorn… - Intractable & rare diseases research, 2016